Gimoti (Metoclopramide HCl) Patent Expiration, LOE Window & CMS Spending
Gimoti (Metoclopramide HCl) by Qol Medical: FDA Orange Book LOE 2038-11-17, 5 AB generics, $6.2M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Qol Medical |
| FDA Application & Pathway | N209388 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-11-17 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $6.2M |
| 2024 Medicare Part D Spend | $4.6M |
| 2024 Medicaid Spend | $1.7M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 32.7% 2-yr change) |